AUPS234402A0 - Anti-tumour polycyclic carboxamides - Google Patents

Anti-tumour polycyclic carboxamides

Info

Publication number
AUPS234402A0
AUPS234402A0 AUPS2344A AUPS234402A AUPS234402A0 AU PS234402 A0 AUPS234402 A0 AU PS234402A0 AU PS2344 A AUPS2344 A AU PS2344A AU PS234402 A AUPS234402 A AU PS234402A AU PS234402 A0 AUPS234402 A0 AU PS234402A0
Authority
AU
Australia
Prior art keywords
polycyclic
carboxamides
tumour
cytotoxicity
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPS2344A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Trobe University
Auckland Uniservices Ltd
Original Assignee
La Trobe University
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Trobe University, Auckland Uniservices Ltd filed Critical La Trobe University
Priority to AUPS2344A priority Critical patent/AUPS234402A0/en
Publication of AUPS234402A0 publication Critical patent/AUPS234402A0/en
Priority to NZ537015A priority patent/NZ537015A/en
Priority to EP03717051A priority patent/EP1507778B1/en
Priority to CA2485494A priority patent/CA2485494C/en
Priority to AU2003221640A priority patent/AU2003221640B2/en
Priority to AT03717051T priority patent/ATE546447T1/de
Priority to JP2004505374A priority patent/JP2005531563A/ja
Priority to PCT/AU2003/000569 priority patent/WO2003097642A1/en
Priority to US10/514,523 priority patent/US7504507B2/en
Priority to US12/372,416 priority patent/US20090156630A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AUPS2344A 2002-05-15 2002-05-15 Anti-tumour polycyclic carboxamides Abandoned AUPS234402A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AUPS2344A AUPS234402A0 (en) 2002-05-15 2002-05-15 Anti-tumour polycyclic carboxamides
US10/514,523 US7504507B2 (en) 2002-05-15 2003-05-12 Anti-tumour polycyclic carboxamides
AU2003221640A AU2003221640B2 (en) 2002-05-15 2003-05-12 Anti-tumour polycyclic carboxamides
EP03717051A EP1507778B1 (en) 2002-05-15 2003-05-12 Anti-tumour polycyclic carboxamides
CA2485494A CA2485494C (en) 2002-05-15 2003-05-12 Anti-tumour polycyclic carboxamides
NZ537015A NZ537015A (en) 2002-05-15 2003-05-12 Anti-tumour polycyclic carboxamides with cytotoxicity
AT03717051T ATE546447T1 (de) 2002-05-15 2003-05-12 Polzcyclische carbonsäureamide mit antitumorwirkung
JP2004505374A JP2005531563A (ja) 2002-05-15 2003-05-12 抗腫瘍性多環式カルボキサミド
PCT/AU2003/000569 WO2003097642A1 (en) 2002-05-15 2003-05-12 Anti-tumour polycyclic carboxamides
US12/372,416 US20090156630A1 (en) 2002-05-15 2009-02-17 Anti-tumour polycyclic carboxamides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPS2344A AUPS234402A0 (en) 2002-05-15 2002-05-15 Anti-tumour polycyclic carboxamides

Publications (1)

Publication Number Publication Date
AUPS234402A0 true AUPS234402A0 (en) 2002-06-13

Family

ID=3835914

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPS2344A Abandoned AUPS234402A0 (en) 2002-05-15 2002-05-15 Anti-tumour polycyclic carboxamides

Country Status (8)

Country Link
US (2) US7504507B2 (https=)
EP (1) EP1507778B1 (https=)
JP (1) JP2005531563A (https=)
AT (1) ATE546447T1 (https=)
AU (1) AUPS234402A0 (https=)
CA (1) CA2485494C (https=)
NZ (1) NZ537015A (https=)
WO (1) WO2003097642A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS234402A0 (en) * 2002-05-15 2002-06-13 Auckland Uniservices Limited Anti-tumour polycyclic carboxamides
AU2005209845A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by N-acetyl transferase genotyping
US20080248134A1 (en) * 2005-05-04 2008-10-09 Auckland Uniservices Limited Oral compositions, use and combinations of N-[2-(dimethylamino)ethyl]-2,6 dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide and closely related analogues thereof
CZ304996B6 (cs) 2013-01-17 2015-03-18 Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. Deriváty helquatů, jejich příprava a použití jako léčiva
CZ307163B6 (cs) 2014-05-29 2018-02-14 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Helquaty s heteroaromatickými substituenty, jejich příprava a použití jako stabilizátory G-kvadruplexů
WO2017097928A1 (en) * 2015-12-08 2017-06-15 Universität Zu Köln Cpap-tubulin module
CN109265396A (zh) * 2018-09-12 2019-01-25 李玮 多环酰胺化合物的合成新方法与抗癌活性
CN115677691B (zh) * 2022-08-24 2023-08-29 潍坊富邦药业有限公司 一种苯并萘啶酰胺抗癌药sn28049及其类似物的制备方法
CN118852160A (zh) * 2024-09-24 2024-10-29 世华合创生物技术开发(山东)有限公司 一种三环酰胺化合物、制备方法及应用
CN119350330B (zh) * 2024-12-23 2025-03-21 世华合创生物技术开发(山东)有限公司 一种二氮杂三环胺化合物、制备方法及其应用
CN119350329B (zh) * 2024-12-23 2025-03-21 世华合创生物技术开发(山东)有限公司 一种二氮杂三环胺化合物、制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
NZ201084A (en) * 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
AUPS234402A0 (en) * 2002-05-15 2002-06-13 Auckland Uniservices Limited Anti-tumour polycyclic carboxamides

Also Published As

Publication number Publication date
CA2485494C (en) 2011-08-23
WO2003097642A1 (en) 2003-11-27
EP1507778A4 (en) 2006-05-31
JP2005531563A (ja) 2005-10-20
EP1507778B1 (en) 2012-02-22
ATE546447T1 (de) 2012-03-15
US7504507B2 (en) 2009-03-17
NZ537015A (en) 2007-06-29
EP1507778A1 (en) 2005-02-23
US20090156630A1 (en) 2009-06-18
US20050245561A1 (en) 2005-11-03
CA2485494A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
TW200531689A (en) Therapeutic agents
MXPA04002682A (es) Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
TW200504034A (en) Therapeutic agents
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
TW200508214A (en) Novel compounds
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
TW200616627A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MXPA04004064A (es) Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2003024935A3 (en) Substituted pyrazolyl compounds for the treatment of inflammation
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
GB2375534B (en) Anti-cancer compounds
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200738659A (en) Novel compounds
WO2003027075A3 (en) Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
WO2004076445A3 (en) Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis